Ads
related to: winrevair fda approval date for evenity 1 day
Search results
Results From The WOW.Com Content Network
Sotatercept, sold under the brand name Winrevair is a medication used for the treatment of pulmonary arterial hypertension. [6] It is an activin signaling inhibitor, [ 6 ] based on the extracellular domain of the activin type 2 receptor expressed as a recombinant fusion protein with immunoglobulin Fc domain (ACTRIIA-Fc). [ 9 ]
The therapy, branded Winrevair, is approved for treating pulmonary arterial hypertension (PAH), which affects about 40,000 people in the United States. US FDA approves Merck's therapy for rare ...
Winrevair, which costs around $238,000 annually, was the first treatment to secure approval from the U.S. Food and Drug Administration from a class of drugs, which target a type of protein called ...
Romosozumab, sold under the brand name Evenity (/ ɪ ˈ v ɛ n ɪ t i / ih-VENN-ih-tee or with the pin-pen merger, / ɪ ˈ v ɪ n ɪ t i / ih-VINN-ih-tee), is a medication used to treat osteoporosis. [ 7 ] [ 8 ] It has been found to decrease the risk of fractures of the spine .
2019: In January, Evenity (romosozumab) received approval in Japan, [76] [77] followed by FDA approval in April. [78] In June, Kanjinti (trastuzumab-anns) was approved by the FDA. [79] Amgen announced it would acquire Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) to enhance its drug discovery capabilities. [80]
While the company has not yet applied for approval from the U.S. Food and Drug Administration, a potential nod could make seralutinib a rival to Merck's Winrevair, which secured the agency's ...
Ads
related to: winrevair fda approval date for evenity 1 day